Molecules secreted by visceral adipocytes in patients with coronary atherosclerosis and insulin resistance

Aim. To study the association of adipocytokine levels with insulin resistance (IR) and stable/unstable plaques in patients with coronary atherosclerosis.

Material and methods. This cross-sectional observational study included 109 men aged 38-79 years with class II-III stable angina pectoris without acute coronary syndrome (ACS), with coronary atherosclerosis verified by coronary angiography. Biochemical tests were carried out using the enzymatic method on a Konelab 30i analyzer at the Laboratory of Clinical Biochemical and Hormonal Studies of Internal Diseases of the Research Institute of Internal and Preventive Medicine — branch of the Federal Research Center Institute of Cytology and Genetics. All patients also underwent anthropometric examination.

Results. Patients with coronary atherosclerosis and IR had higher levels of GIP by 1,4 times (p=0,005), GLP-1 by 1,7 times (p=0,032), IL-6 by 3,2 times (p=0,017), leptin by 2,3 times (p=0,001) and pancreatic polypeptide (PP) by 1,9 times (p=0,006). In patients with stable plaques and IR, leptin was 2 times higher, and PP was 1,7 times higher, compared to patients without IR. In patients with unstable plaques and IR, leptin and PP levels are 5,1 and 1,7 times higher, respectively, compared to the group of patients without IR. In patients with IR and stable plaques, PYY was 1,5 times higher than in patients with IR and unstable plaques, while the adiponectin level was 1,9 times higher. Logistic regression analysis demonstrated that PP is associated with IR in patients with unstable plaques.

Conclusion. Patients with coronary atherosclerosis and IR had higher levels of GIP, GLP-1, IL-6, leptin and PP. Leptin and PP levels are higher in patients with both stable and unstable plaques and IR, and PYY and adiponectin levels are higher in patients with stable plaques and IR compared with patients without IR. PP is associated with IR in patients with unstable plaques.

1. Sizova EE. Insulin resistance — a role in the pathogenesis of metabolic syndrome. Endocrinology: news, opinions, training. 2020;9(4):98-100. (In Russ.) doi:10.33029/2304-9529-2020-9-4-98-100.

2. Kashtanova EV, Polonskaya YaV, Shcherbakova LV, et al. Associations of adupocutokine and metaboliv hormone level in young people aged 25-44 years with type 2 diabetes mellitus and abdominal obesity. Obesity and metabolism. 2024;21(1):14-23. (In Russ.) doi:10.14341/omet12974.

3. Kazakova MI, Vysotskaya EA, Mitkovskaya NP. The role of inflammation in the pathogenesis of atherosclerosis. Emergency Cardiology and Cardiovascular Risks. 2022;6(2):1707-13. (In Russ.) doi:10.51922/2616-633X.2022.6.2.1707.

4. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-38. doi:10.1016/j.jacc.2009.09.009.

5. Waksman Ron; Patrick W. Serruys; Schaar, J. Handbook of the Vulnerable Plaque; 2nd ed.; CRC Press: London, 2007; ISBN: 978-1841846217.

6. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Develo­ped by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European heart journal. 2021;42(34)3227-337. doi:10.1093/eurheartj/ehac458.

7. Gutch M, Kumar S, Razi SM, et al. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19(1):160-4. doi:10.4103/2230-8210.146874.

8. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014.

9. Mustafina IA, Ionin VA, Dolganov AA, et al. Role of epicardial adipose tissue in the development of cardiovascular diseases. Russian Journal of Cardiology. 2022;27(1S):4872.(In Russ.) doi:10.15829/1560-4071-2022-4872.

10. Mechanick JI, Zhao S, Garvey WT. Leptin, an adipokine with central importance in the global obesity problem. Glob Heart. 2018;13:113-27. doi:10.1016/j.gheart.2017.10.003.

11. Raman P, Khanal S. Leptin in Atherosclerosis: Focus on Macrophages, Endothelial and Smooth Muscle Cells. Int J Mol Sci. 2021;22(11):5446. doi:10.3390/ijms22115446.

12. Georgakis MK, Malik R, Richardson TG, et al. Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups. BMC Med. 2022;20:245. doi:10.1186/s12916-022-02446-6.

13. Konstantinides S, Schäfer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. Journal of Clinical Investigation. 2001;108(10):1533-40. doi:10.1172/JCI13143.

14. Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol. Sin. 2018;(39):1176-88. doi:10.1038/aps.2018.40.

15. Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular disease. J. Cardiol. 2013;63:250-9. doi:10.1016/j.jjcc.2013.11.006.

16. Liu L, Shi Z, Ji X, et al. Adipokines, adiposity, and atherosclerosis. Cell. Mol. Life Sci. 2022;79:272. doi:10.1007/s00018-022-04286-2.

17. Yan C.-J, Li S-M, Xiao Q, et al. Influence of serum adiponectin level and SNP +45 poly­mor­phism of adiponectin gene on myocardial fibrosis. J. Zhejiang Univ. Sci. B. 2013;14:721-8. doi:10.1631/jzus.BQICC707.

18. Park M, Sweeney G. Direct effects of adipokines on the heart: Focus on adiponectin. Heart Fail. Rev. 2012;18:631-44. doi:10.1007/s10741-012-9337-8.

19. Marso SP, Mehta SK, Frutkin A, et al. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care. 2008;31:989-94. doi:10.2337/dc07-2024.

20. Csongrádi É, Káplár M, Nagy Jr B, et al. Adipokines as atherothrombotic risk factors in obese subjects: Associations with haemostatic markers and common carotid wall thickness. Nutr. Metab. Cardiovasc. Dis. 2017;27:571-80. doi:10.1016/j.numecd.2017.02.007.

21. Khavkin AI, Gurina OP, Dementieva EA, et al. Modern possibilities of laboratory diagnosis of disorders of the gastrointestinal tract. Experimental and Clinical Gastroenterology. 2020;(6):173-85. (In Russ.) doi:10.31146/1682-8658-ecg-178-6-173-185.

22. Haj-Yehia E, Mer tens RW, Kahles F, et al. Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction. J Clin Med. 2020;9(12):3952. doi:10.3390/jcm9123952.

23. Ramracheya RD, McCulloch LJ, Clark A, et al. PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery. Cell Rep. 2016;15(5):944-50. doi:10.1016/j.celrep.2016.03.091.

24. Khan DS, Vasu RC, Moffett N, et al. Flatt Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival Biochim. Et. Biophys. Acta Gen. Subj. 2017;1861(4):749-58. doi:10.1016/j.bbagen.2017.01.005.

25. Aragón F, Karaca M, Novials A, et al. Rubí Pancreatic polypeptide regulates glucagon release through PPYR1 receptors expressed in mouse and human alpha-cells Biochim. Biophys. Acta BBA Gen. Subj. 2015;1850:343-51. doi:10.1016/j.bbagen.2014.11.005.

26. Kim W, Fiori JL, Shin Y-K, et al. Egan Pancreatic polypeptide inhibits somatostatin secretion FEBS Lett. 2014;588:3233-9. doi:10.1016/j.febslet.2014.07.005.

27. Zhu W, Tanday N, Flatt PR, et al. Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes. Peptides. 2023;160:170923. doi:10.1016/j.peptides.2022.170923.

28. Bays HE, Jones PH, Orringer CE, et al. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016;10(1 Suppl):S1-43. doi:10.1016/j.jacl.2015.08.002.